Opiant Pharmaceuticals Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine

SANTA MONICA, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ( “Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today reports that new pre-clinical data...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials